Akari Therapeutics, Plc
AKTX
$10.73
$1.2112.71%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.74M | 9.28M | 10.19M | 9.92M | 9.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.20M | 12.10M | 13.16M | 12.79M | 15.23M |
| Operating Income | -12.20M | -12.10M | -13.16M | -12.79M | -15.23M |
| Income Before Tax | -29.91M | -18.30M | -16.86M | -12.27M | -17.93M |
| Income Tax Expenses | -1.86M | -1.00M | -1.09M | -- | -- |
| Earnings from Continuing Operations | -28.05 | -17.30 | -15.77 | -12.27 | -17.93 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.05M | -17.30M | -15.77M | -12.27M | -17.93M |
| EBIT | -12.20M | -12.10M | -13.16M | -12.79M | -15.23M |
| EBITDA | -8.56M | -12.08M | -13.15M | -12.78M | -15.22M |
| EPS Basic | -1.99M | -1.65M | -1.88M | -2.01M | -4.38M |
| Normalized Basic EPS | -6.06 | -8.09 | -11.11 | -13.22 | -25.80 |
| EPS Diluted | -1.99M | -1.65M | -1.88M | -2.01M | -4.38M |
| Normalized Diluted EPS | -6.06 | -8.09 | -11.11 | -13.22 | -25.80 |
| Average Basic Shares Outstanding | 4.17M | 3.37M | 2.77M | 2.26M | 1.71M |
| Average Diluted Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |